ELISA Kit for Osteopontin (OPN)
SPP1; BNSP; BSPI; ETA1; Secreted Phosphoprotein 1; Bone Sialoprotein I; Early T-Lymphocyte Activation 1; Nephropontin; Urinary stone protein; Uropontin
- Product No.SEA899Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample Typeserum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Range0.625-40ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.263ng/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
For more details, please contact local distributors! US$ 438
For more details, please contact local distributors! US$ 1971
For more details, please contact local distributors! US$ 3723
For more details, please contact local distributors! US$ 30660
For more details, please contact local distributors!
This assay has high sensitivity and excellent specificity for detection of Osteopontin (OPN).
No significant cross-reactivity or interference between Osteopontin (OPN) and analogues was observed.
Matrices listed below were spiked with certain level of recombinant Osteopontin (OPN) and the recovery rates were calculated by comparing the measured value to the expected amount of Osteopontin (OPN) in samples.
|Matrix||Recovery range (%)||Average(%)|
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Osteopontin (OPN) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Osteopontin (OPN) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Osteopontin (OPN) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
|Pre-coated, ready to use 96-well strip plate||1||Plate sealer for 96 wells||4|
|Detection Reagent A||1×120µL||Assay Diluent A||1×12mL|
|Detection Reagent B||1×120µL||Assay Diluent B||1×12mL|
|TMB Substrate||1×9mL||Stop Solution||1×6mL|
|Wash Buffer (30 × concentrate)||1×20mL||Instruction manual||1|
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
|Journal of Biomedical Materials Research Part A||Proliferation and osteogenesis of immortalized bone marrow-derived mesenchymal stem cells in porous polylactic glycolic acid scaffolds under perfusion culture PubMed: 19280635|
|Osteoarthritis and Cartilage||Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patients PubMed: 19747583|
|The Journal of Rheumatology||Thrombin-cleaved osteopontin levels in synovial fluid correlate with disease severity of knee osteoarthritis. Jrheum: source|
|International Journal of Pharmaceutics||Suppression of tumor growth in xenograft model mice by small interfering RNA targeting osteopontin delivery using biocompatible poly(amino ester) ScienceDirect: S0378517312003742|
|European Cells and matreials||The use of non-viral gene vectors for bioactive poly-(D, L-lactide) implant surfaces in bone tissue engineering Ecmjournal: Source|
|Journal of Equine Veterinary Science||Influence of Seminal Plasma Antioxidants and Osteopontin on Fertility of the Arabian Horse ScienceDirect: Source|
|Basic & Clinical Pharmacology & Toxicology||Treatment with Carnitine Enhances Bone Fracture Healing under Osteoporotic and/or Inflammatory Conditions Wiley:Source|
|Journal of Cellular Biochemistry||Tension Force-Induced ATP Promotes Osteogenesis Through P2X7 Receptor in Osteoblasts Pubmed:24905552|
|Naunyn-Schmiedeberg's Archives of Pharmacology||Treatment with α-lipoic acid enhances the bone healing after femoral fracture model of rats Pubmed:25038619|
|J Endocrinol Invest.?||The interplay among iron metabolism, endothelium and inflammatory cascade in dysmetabolic disorders Pubmed:25245337|
|FEBS Letters||Low-intensity pulsed ultrasound-induced ATP increases bone formation via the P2X7 receptor in osteoblast-like MC3T3-E1 cells Pubmed:25542352|
|Gene||Effects of magnesium degradation products on mesenchymal stem cell fate and osteoblastogenesis PubMed: 26283150|
|Medicine (Baltimore)||An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic Cancer PubMed: 26266370|
|Journal of Biomaterials and Tissue Engineering||Osteogenic Differentiation of Canine Adipose Stem Cells Cultured in Alginate-Fibrin-Based Hydrogel Content: Asp|
|Primasari||Osteopontin level correlates negatively with tumor shrinkage in neoadjuvant chemoradiation of locally advanced rectal cancer Index.Php: Amor|
|Int J Biol Sci||Defective Initiation of Liver Regeneration in Osteopontin-Deficient Mice after Partial Hepatectomy due to Insufficient Activation of IL-6/Stat3 Pathway PubMed: 26327817|
|Journal of Kunming Medical University / Kunming Yike Daxue Xuebao||Perioperative Clinical Investigation of Serum VEGF, CA19-9 and OPN Levels in Patients with Colorectal Carcinoma. Ebscohost|
|Am J Pathol.||Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy. Pubmed:26963343|
|circulation journal||Stenotic Bicuspid and Tricuspid Aortic Valves - Micro-Computed Tomography and Biological Indices of Calcification. pubmed:28344201|
|Journal of Cardiovascular Electrophysiology||Effect of Cardiac Resynchronization Therapy on Myocardial Fibrosis and Relevant Cytokines in a Canine Model With Experimental Heart Failure. pubmed:28127817|
|American Journal of Translational Research||Osteopontin stimulates matrix metalloproteinase expression through the nuclear factor-κB signaling pathway in rat temporomandibular joint and condylar chondrocytes. pubmed:28337262|
|Diabetes Care||Targeted Microbiome Intervention by Microencapsulated Delayed-Release Niacin Beneficially Affects Insulin Sensitivity in Humans pubmed:29212824|
|Biomedicine & pharmacotherapy||Icaritin induces MC3T3-E1 subclone14 cell differentiation through estrogen receptor-mediated ERK1/2 and p38 signaling activation. pubmed:28742995|
|Catalog No.||Related products for research use of Homo sapiens (Human) Organism species||Applications (RESEARCH USE ONLY!)|
|EPA899Hu61||Eukaryotic Osteopontin (OPN)||Positive Control; Immunogen; SDS-PAGE; WB.|
|RPA899Hu02||Recombinant Osteopontin (OPN)||Positive Control; Immunogen; SDS-PAGE; WB.|
|APA899Hu61||Active Osteopontin (OPN)||Cell culture; Activity Assays.|
|PAA899Hu06||Polyclonal Antibody to Osteopontin (OPN)||WB; IHC; ICC; IP.|
|PAA899Hu02||Polyclonal Antibody to Osteopontin (OPN)||WB; IHC; ICC; IP.|
|LAA899Hu71||Biotin-Linked Polyclonal Antibody to Osteopontin (OPN)||WB; IHC; ICC.|
|MAA899Hu22||Monoclonal Antibody to Osteopontin (OPN)||WB; IHC; ICC; IP.|
|SEA899Hu||ELISA Kit for Osteopontin (OPN)||Enzyme-linked immunosorbent assay for Antigen Detection.|
|SCA899Hu||CLIA Kit for Osteopontin (OPN)||Chemiluminescent immunoassay for Antigen Detection.|
|KSA899Hu01||ELISA Kit DIY Materials for Osteopontin (OPN)||Main materials for "Do It (ELISA Kit) Yourself".|